 Gene Expression Regulation, Neoplastic
"Gene Expression Regulation, Neoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
| Descriptor ID |
D015972
|
| MeSH Number(s) |
G05.308.370
|
| Concept/Terms |
Gene Expression Regulation, Neoplastic- Gene Expression Regulation, Neoplastic
- Regulation of Gene Expression, Neoplastic
- Regulation, Gene Expression, Neoplastic
- Neoplastic Gene Expression Regulation
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Neoplastic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Neoplastic".
This graph shows the total number of publications written about "Gene Expression Regulation, Neoplastic" by people in this website by year, and whether "Gene Expression Regulation, Neoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 | | 1997 | 2 | 1 | 3 | | 1998 | 2 | 2 | 4 | | 1999 | 5 | 2 | 7 | | 2000 | 3 | 4 | 7 | | 2001 | 3 | 2 | 5 | | 2002 | 12 | 8 | 20 | | 2003 | 4 | 9 | 13 | | 2004 | 7 | 11 | 18 | | 2005 | 14 | 6 | 20 | | 2006 | 13 | 19 | 32 | | 2007 | 14 | 10 | 24 | | 2008 | 11 | 20 | 31 | | 2009 | 7 | 16 | 23 | | 2010 | 12 | 26 | 38 | | 2011 | 8 | 21 | 29 | | 2012 | 11 | 26 | 37 | | 2013 | 14 | 29 | 43 | | 2014 | 12 | 28 | 40 | | 2015 | 11 | 32 | 43 | | 2016 | 13 | 45 | 58 | | 2017 | 7 | 40 | 47 | | 2018 | 16 | 37 | 53 | | 2019 | 15 | 28 | 43 | | 2020 | 19 | 21 | 40 | | 2021 | 9 | 24 | 33 | | 2022 | 0 | 8 | 8 | | 2023 | 1 | 4 | 5 | | 2024 | 4 | 28 | 32 | | 2025 | 6 | 33 | 39 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Gene Expression Regulation, Neoplastic" by people in Profiles.
-
Selvam K, Lu S, Messmer C, Pang Y, Biswas S, Khalil M, Zhang P, Tulaiha R, Zhou MM, Kitamura T, Lauberth SM, Blanco MA, Yang FC, Affar EB, Zhao Z, Zeng L, Wang L, Kutateladze TG. Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4. Nat Commun. 2026 Feb 17; 17(1).
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 02 02; 40(3-4):199-214.
-
Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Watanabe A, Yang C, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells. 2026 Jan 05; 15(1).
-
Fernandez B, Passanisi VJ, Ashraf HM, Spencer SL. Single-cell RNA sequencing reveals a quiescence-senescence continuum and distinct senotypes following chemotherapy. Nat Commun. 2025 Dec 23; 17(1):169.
-
Wang D, Ritz C, Luo Y, Suresh A, Pierce A, Veo B, Brunt B, Dahl N, Serkova N, Venkataraman S, Danis E, Kus K, Mazan M, Rzymski T, Vibhakar R. Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. Nat Commun. 2025 Dec 16; 16(1):11152.
-
Kurayoshi K, Tanaka M, Nakajima R, Zhou Y, Shirasawa M, Fikriyanti M, Fujisawa JI, Iwanaga R, Bradford AP, Araki K, Ohtani K. Utility of Tumor Suppressor E2F Target Gene Promoter Elements to Drive Gene Expression Specifically in Cancer Cells. Cells. 2025 Dec 09; 14(24).
-
Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N, Hayashi M, Raredon MSB, Amatruda JF. Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas. Clin Cancer Res. 2025 Dec 01; 31(23):5051-5069.
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Geng D, Chen J, Sanchez A, Davalos SA, Wilcox P, Gonzales-Rivera D, Couts K, Tobin R, Robinson W, Nielsen AJ, Guo J, McCarter M, Crump L, Tsujimoto K, Wilky BA, Davila E. Melanoma leverages innate immune IRAK-M signaling to limit metastasis through PTPN22-Induced signaling repression. Cancer Lett. 2026 Feb 28; 639:218172.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|